Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

BACKGROUND: β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-ef...

詳細記述

保存先:
書誌詳細
出版年:Alzheimers Res Ther
主要な著者: Doecke, James D., Ward, Larry, Burnham, Samantha C., Villemagne, Victor L., Li, Qiao-Xin, Collins, Steven, Fowler, Christopher J., Manuilova, Ekaterina, Widmann, Monika, Rainey-Smith, Stephanie R., Martins, Ralph N., Masters, Colin L.
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2020
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7110644/
https://ncbi.nlm.nih.gov/pubmed/32234072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-020-00595-5
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料